Emma Walmsley will succeed Andrew Witty next year and become the seventh female chief executive in the FTSE 100.
GSK today announced that Emma Walmsley, currently Chief Executive Officer of GSK’s Consumer Healthcare division, has been appointed GSK CEO Designate and will succeed Andrew Witty when he retires on March 31, 2017. Walmlsey will join the GSK Board of Directors from January 1, 2017. She has been a member of GSK’s Corporate Executive Team since 2011, joining the company in 2010 from L’Oreal where she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. The appointment sees Walmsley, 47, become the seventh female chief executive in the FTSE 100, The Telegraph reported, and makes her "arguably the most powerful female boss in the index".
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.